ATA188 ‘Game Changing’ for Progressive MS & Ublituximab Superior to Aubagio episode artwork

EPISODE · Nov 16, 2022 · 25 MIN

ATA188 ‘Game Changing’ for Progressive MS & Ublituximab Superior to Aubagio

from MS News & Perspectives · host MS News Today

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, reads a news report on ATA188, a treatment targeting the Epstein-Barr virus which could be integral in treating progressive MS.He also reads a news article reporting on how ublituximab works better than Aubagio at easing disability in patients with relapsing MS.=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:https://multiplesclerosisnewstoday.com/=====================================To join in on conversations regarding multiple sclerosis, please visit:https://multiplesclerosisnewstoday.com/forums/

Episode metadata supplied by the publisher feed · Published Nov 16, 2022

Embed this episode

NOW PLAYING

ATA188 ‘Game Changing’ for Progressive MS & Ublituximab Superior to Aubagio

0:00 25:14

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MS News & Perspectives?

This episode is 25 minutes long.

When was this MS News & Perspectives episode published?

This episode was published on November 16, 2022.

Can I download this MS News & Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!